Acetylated-Lysine Antibody

9441:

ChIP Agarose , ChIP Magnetic , ELISA Peptide , IHC / Paraffin , Immunofluorescence , Immunoprecipitation , Western Blotting

Acetylated-Lysine Antibody detects proteins posttranslationally modified by acetylation on the epsilon-amine groups of lysine residues. The antibody recognizes acetylated lysine in a wide range of sequence contexts. It has been demonstrated to recognize acetylated histones, p53, CBP, PCAF and chemically acetylated BSA. The antibody has been shown to react with as little as 0.04 ng of chemically acetylated BSA while not recognizing up to 25 µg of nonacetylated BSA. (U.S. Patent No's.: 6,441,140; 6,982,318; 7,259,022; 7,344,714; U.S.S.N. 11,484,485; and all foreign equivalents.)

Polyclonal antibodies are produced by immunizing animals with a synthetic acetylated lysine-containing peptide. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western blot analysis of extracts from NIH/3T3 cells, untreated or sodium butyrate-treated (5 mM for 24 hours), showing an increase in histone acetylation using Acetylated-Lysine Antibody.

Western Blotting

Specificity and sensitivity of Acetylated-Lysine Antibody assayed on acetylated BSA (4; 1; 0.2; 0.04 or 0.008 ng in lanes 1-5) or nonacetylated BSA (25,000; 5,000; 1,000 or 200 ng in lanes 6-9).

Western Blotting

Western blot analysis of extracts from COS cells, untreated or TSA-treated, grown in 10% FBS (lanes 1 and 2) or serum starved for 18 hours (lanes 3 and 4), using Acetylated-Lysine Antibody (upper) or p44/42 MAP Kinase Antibody #9102 (lower).

IP

Western blot analysis of immunoprecipitated p53 showing an increase in p53 acetylation using Acetylated-Lysine Antibody (upper) or p53 antibody (lower). p53 was immunoprecipitated from lysates from 293 cells, untreated or UV-treated, using p53 Antibody #9282.

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human colon carcinoma using Acetylated-Lysine Antibody.

IHC-P (paraffin)

Immunohistochemical staining of a paraffin-embedded human breast tumor section showing nuclear and cytoplasmic localization of proteins with acetylated lysine residues using Acetylated-Lysine Antibody.

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded NIH/3T3 untreated (left) or TSA-treated (right) using Acetylated-Lysine Antibody.

IF-IC

Confocal immunofluorescent analysis of NIH/3T3 cells, untreated (left) or SAHA-treated (right), labeled with Acetylated-Lysine Antibody (green). Actin filaments have been labeled with Alexa Fluor R 555 phalloidin (red). Blue pseudocolor = DRAQ5^® #4084 (fluorescent DNA dye).

Chromatin IP

Chromatin immunoprecipitations were performed with cross-linked chromatin from 4 x 10⁶ HeLa cells and either 10 μl of Acetylated-Lysine Antibody or 2 μl of Normal Rabbit IgG #2729, using SimpleChIP^® Enzymatic Chromatin IP Kit (Agarose Beads) #9002. The enriched DNA was quantified by real-time PCR, using SimpleChIP^® Human GAPDH Exon 1 Primers #5516, SimpleChIP^® Human RPL30 Exon 3 Primers #7014, SimpleChIP^® Human MyoD1 Exon 1 Primers #4490, and SimpleChIP^® Human MYT-1 Exon 1 Primers #4493. The amount of immunoprecipitated DNA in each sample is represented as signal relative to the total amount of input chromatin, which is equivalent to one.

Acetylation of lysine, like phosphorylation of serine, threonine or tyrosine, is an important reversible modification controlling protein activity. The conserved amino-terminal domains of the four core histones (H2A, H2B, H3, and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (1). Signaling resulting in acetylation/deacetylation of histones, transcription factors, and other proteins affects a diverse array of cellular processes including chromatin structure and gene activity, cell growth, differentiation, and apoptosis (2-6). Recent proteomic surveys suggest that acetylation of lysine residues may be a widespread and important form of posttranslational protein modification that affects thousands of proteins involved in control of cell cycle and metabolism, longevity, actin polymerization, and nuclear transport (7,8). The regulation of protein acetylation status is impaired in cancer and polyglutamine diseases (9), and HDACs have become promising targets for anti-cancer drugs currently in development (10).

1. Hassig, C.A. and Schreiber, S.L. (1997) Curr Opin Chem Biol 1, 300-8.
2. Allfrey, V.G. et al. (1964) Proc Natl Acad Sci USA 51, 786-94.
3. Liu, L. et al. (1999) Mol Cell Biol 19, 1202-9.
4. Boyes, J. et al. (1998) Nature 396, 594-8.
5. Polevoda, B. and Sherman, F. (2002) Genome Biol 3, reviews0006.
6. Yoshida, M. et al. (2003) Prog Cell Cycle Res 5, 269-78.
7. Kim, S.C. et al. (2006) Mol Cell 23, 607-18.
8. Choudhary, C. et al. (2009) Science 325, 834-40.
9. Hughes, R.E. (2002) Curr Biol 12, R141-3.
10. Vigushin, D.M. and Coombes, R.C. (2004) Curr Cancer Drug Targets 4, 205-18.

• Werner, H.B. et al. (2007) J Neurosci 27, 7717-30. Applications: Western Blotting
• Yuan, Z.L. et al. (2005) Science 307, 269-73. Applications: Western Blotting
• Hu, J. and Colburn, N.H. (2005) Mol Cancer Res 3, 100-9. Applications: Western Blotting
• Kurahashi, T. et al. (2005) Mol Biol Cell 16, 4705-13. Applications: Western Blotting
• Wang, R. et al. (2005) J Biol Chem 280, 11528-34. Applications: Western Blotting
• Chen, L. et al. (2005) Mol Cancer Ther 4, 1311-9. Applications: Western Blotting
• Zheng, G. and Yang, Y.C. (2005) J Biol Chem 280, 40773-81. Applications: Western Blotting
• Qiu, Y. et al. (2004) J Biol Chem 279, 9796-802. Applications: IP
• Ard, P.G. et al. (2002) Mol Cell Biol 22, 5650-61. Applications: IP
• Yu, X. et al. (2002) J Natl Cancer Inst 94, 504-13. Applications: Western Blotting
• Bereshchenko, O.R. et al. (2002) Nat Genet 32, 606-13. Applications: Western Blotting
• Chen Lf et al. (2001) Science 293, 1653-7. Applications: Western Blotting
• Mal, A. et al. (2001) EMBO J 20, 1739-53. Applications: Western Blot
• Sano, Y. and Ishii, S. (2001) J Biol Chem 276, 3674-82. Applications: Western Blotting
• Chan, H.M. et al. (2001) Nat Cell Biol 3, 667-74. Applications: Western Blot
• Fu, M. et al. (2000) J Biol Chem 275, 20853-60. Applications: IP
• Li, S. et al. (2000) Proc Natl Acad Sci U S A 97, 7166-71. Applications: Western Blot
• Martínez-Balbás, M.A. et al. (2000) EMBO J 19, 662-71. Applications: Immunoprecipitation

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know !

• 9681 Acetylated-Lysine Mouse mAb (Ac-K-103)
• 2062 Histone Deacetylase 1 (HDAC1) Antibody
• 2072 Histone Deacetylase 4 (HDAC4) Antibody
• 2082 Histone Deacetylase 5 (HDAC5) Antibody
• 2152 WSTF Antibody
• 9715 Histone H3 Antibody
• 9701 Phospho-Histone H3 (Ser10) Antibody
• 9706 Phospho-Histone H3 (Ser10) (6G3) Mouse mAb
• 9671 Acetyl-Histone H3 (Lys9) Antibody
• 9711 Acetyl- and Phospho-Histone H3 (Lys9/Ser10) Antibody
• 7071 Phototope^® -HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
• 7074 Anti-rabbit IgG, HRP-linked Antibody
• 7720 Prestained Protein Marker, Broad Range (Premixed Format)
• 7727 Biotinylated Protein Ladder Detection Pack
• 7003 20X LumiGLO^® Reagent and 20X Peroxide

License/Use Restrictions: Use of CST Motif Antibodies within certain methods (e.g., U.S. Patent No.'s 7,198,896 & 7,300,753) may require a license from CST. For information regarding academic licensing terms please have your technology transfer office contact CST Legal Department at CST_ip@cellsignal.com. For information regarding commercial licensing terms please contact CST Pharma Services Department at ptmscan@cellsignal.com.

For Research Use Only. Not For Use In Diagnostic Procedures.